CSIMarket Company Name, Ticker, Industry, else..


Gamida Cell Ltd   (NASDAQ: GMDA)
Other Ticker:  
 

Gamida Cell Ltd

GMDA's Fundamental analysis



Looking into Gamida Cell Ltd growth rates, revenue grew in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 263

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -1.28 %

Gamida Cell Ltd 's net profit decreased by -12.5 % in I. Quarter 2024 year on year, to $20 millions.

• More on GMDA's Growth


Gamida Cell Ltd
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Gamida Cell Ltd realized cash reduction of $ -0.17 per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
0.06
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.91.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.


• More on GMDA's Valuation
 
 Total Debt (Millions $) 75
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 15,949
 Net Income/Employee (TTM) $ 219,031
 Receivable Turnover (TTM) 3.67
 Tangible Book Value (Per Share $) -0.12

Gamida Cell Ltd
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Gamida Cell Ltd realized cash outflow of $ -0.17per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
0.06
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.91.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.


• More on GMDA's Valuation

•  Market Capitalization (Millions $) 6
•  Shares Outstanding (Millions) 153
•  Employees 98
•  Revenues (TTM) (Millions $) 2
•  Net Income (TTM) (Millions $) 21
•  Cash Flow (TTM) (Millions $) -26
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) 75
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 15,949
•  Net Income/Employee(TTM) $ 219,031
•  Receivable Turnover Ratio (TTM) 3.67
•  Tangible Book Value (Per Share $) -0.12

•  Market Capitalization (Millions $) 6
•  Shares Outstanding (Millions) 153
•  Employees 98
•  Revenues (TTM) (Millions $) 2
•  Net Income (TTM) (Millions $) 21
•  Cash Flow (TTM) (Millions $) -26
•  Capital Exp. (TTM) (Millions $) -1


    GMDA's Profitability Comparisons
Gamida Cell Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 2824.27 % from 2680.24 % in III. Quarter.

Gamida Cell Ltd net profit margin of 2241.12 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 2 in Healthcare sector and number 13 in S&P 500.





  Ratio
•   Capital Ratio (MRQ) 0.35
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.02
•  Inventory Turnover Ratio (TTM) 0.92



Gamida Cell Ltd achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in I. Quarter 2024 to 2824.27 % from 2680.24 % in III. Quarter.

Gamida Cell Ltd net profit margin of 2241.12 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 2 in Healthcare sector and number 13 in S&P 500.

• More on GMDA's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com